Mironid reach­es $43.7M to date in Se­ries A ex­ten­sion to fund kid­ney dis­ease treat­ment stud­ies

Mironid has raised a to­tal of £35 mil­lion ($43.7 mil­lion) since its in­cep­tion with the help of a Se­ries A ex­ten­sion raise, set­ting it up to get its lead kid­ney dis­ease pro­gram through IND-en­abling de­vel­op­ment.

The ex­ten­sion saw new Big Phar­ma backer Roche Ven­ture Fund join Mironid’s ex­ist­ing in­vestors, which in­clude Ep­i­darex Cap­i­tal and Sofinno­va Part­ners. The raise fol­lows on from an orig­i­nal Se­ries A round of £4.3 mil­lion that the Scot­tish com­pa­ny com­plet­ed back in June 2016.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER